Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This trial will investigate the combination of bevacizumab, and erlotinib in patients with
adenocarcinoma or poorly differentiated carcinoma of unknown primary site. Bevacizumab and
erlotinib are relatively well-tolerated and have non-overlapping toxicity profiles. This
trial will be one of the first clinical trials to evaluate a combination of targeted agents
in the treatment of a solid tumor.